Records 1 - 4
| Monitoring of peripheral blood cluster of differentiation 4 adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases.
Experimental and therapeutic medicine 2018 Jan 15 (1): 532-538.
Muraki Yuichi, Mizuno Shugo, Nakatani Kaname, Wakabayashi Hiroki, Ishikawa Eiji, Araki Toshimitsu, Taniguchi Akira, Isaji Shuji, Okuda Masahi
| Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.
Pharmacogenomics 2017 Oct .
Kumaraswami Konda, Katkam Shiva Krishna, Aggarwal Amita, Sharma Aman, Manthri Ramesh, Kutala Vijay Kumar, Rajasekhar Li
| Effects of CYP3A5 polymorphism and the tacrolimus 12?h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis.
Xenobiotica; the fate of foreign compounds in biological systems 2015 Jul 1-7.
Niioka Takenori, Komatsuda Atsushi, Kato Shotaro, Togashi Masaru, Okuyama Shin, Omokawa Ayumi, Nara Mizuho, Wakui Hideki, Takahashi Naoto, Miura Masato
| Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Arthritis and rheumatism 2004 Jul 50 (7): 2202-10.
Takada Kazuki, Arefayene Million, Desta Zeruesenay, Yarboro Cheryl H, Boumpas Dimitrios T, Balow James E, Flockhart David A, Illei Gabor